Peptides DB
Research-centric peptide and protocol reference hub
Study 12 of 12Tesamorelin literatureBMJ open · RCTTop journal2026

Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV (TRIUMPH): a clinical trial protocol.

The TRIUMPH study is examining whether tesamorelin combined with exercise can improve physical function in older adults living with HIV, but results are not yet available.

Read at BMJ openAdd to compare

Where it sits

this study against the rest of the tesamorelin corpus
1
Preclinical
2
Observational
0
Open-label
7
Randomised · this one
2
Reviews

Summary and findings

The TRIUMPH study investigates the combined effect of tesamorelin and exercise on physical function in 100 sedentary older adults living with HIV. Participants will receive either tesamorelin or placebo for 24 weeks alongside a home-based exercise program. The study aims to assess both clinical and biological endpoints at Weeks 24 and 48.

How much of this paper we could read: partial text (0.50). We had some abstract detail. Check the source for anything decisive. What this means →
2026

Abstract

The authors’ words, as BMJ open supplied them

<h4>Background</h4>The Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV (TRIUMPH) study is a randomised controlled trial with the overall goal of examining the combined effect of exercise and the growth hormone-releasing hormone analogue tesamorelin on physical function.<h4>Methods</h4>TRIUMPH is a two-site, double-blind, randomised trial of 100 sedentary older adults (aged 50-80 years) living with HIV who are frail or at risk for frailty and have excess abdominal adiposity. Enrolled participants will be randomised to receive tesamorelin or placebo as an adjunct to a home-based semisupervised exercise programme for 24 weeks, followed by a 24-week extension phase of independent exercise. We will determine short-term and sustained effects of tesamorelin plus exercise on clinical endpoints, including physical function, muscle content and quality, quality of life, and exercise adherence at Weeks 24 and 48. We also will elucidate effects of tesamorelin plus exercise on biological endpoints, including muscle fat and mitochondrial function at Week 24.<h4>Ethics and dissemination</h4>Ethical approval for the TRIUMPH study was obtained from the Institutional Review Boards at participating sites. All participants provide written informed consent prior to enrolment. Study findings will be disseminated through peer-reviewed publications and scientific conferences and may inform future interventions to improve physical function among older adults living with HIV.<h4>Trial registration number</h4>NCT06554717.

Background

Not reported in abstract.

Methods

Not reported in abstract.

Results

Not reported in abstract.

Interpretation

Not reported in abstract.

Limitations

Not reported in abstract.

Elsewhere in the Tesamorelin corpus

AThe effect of growth hormone-releasing hormone on cognition and brain connectivity in adults with cognition ranging from normal to mild cognitive impairment.eNeurologicalSci · 2026 · Not reported in abstract.HumanAEffect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial.JAMA · 2014 · n=83 · -34 cm2 mean change in visceral adipose tissue with tesamorelin vs 8 cm2 with placebo; P=0.005.HumanARelationship of IGF-1 and IGF-Binding Proteins to Disease Severity and Glycemia in Nonalcoholic Fatty Liver Disease.The Journal of clinical endocrinology and metabolism · 2021 · Not reported in abstract.HumanBThe relationship between acromegaly and hepatic steatosis: insights from FibroScan imaging.europepmc · 2026 · CAP scores: 241.8 ± 50.0 dB/m in acromegaly patients, 281.7 ± 61.2 dB/m in metabolically matched controls, p < 0.001.HumanATesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV (TRIUMPH): a clinical trial protocol.europepmc · 2026HumanAThe effect of growth hormone-releasing hormone on cognition and brain connectivity in adults with cognition ranging from normal to mild cognitive impairment.europepmc · 2026 · Not reported in abstract.Human